{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T18:16:39Z","timestamp":1774894599735,"version":"3.50.1"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000864","name":"Michael J. Fox Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000864","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012205","name":"Saint Mary\u2019s Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012205","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000864","name":"Michael J. Fox Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000864","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012205","name":"Saint Mary\u2019s Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012205","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000864","name":"Michael J. Fox Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000864","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"Abbvie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014392","name":"Avid Radiopharmaceuticals","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100014392","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]},{"name":"BioLegend"},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006775","name":"GE Healthcare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006775","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Golub Capital"},{"DOI":"10.13039\/100004330","name":"GSK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Lilly","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003554","name":"Lundbeck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003554","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007054","name":"Meso Scale Diagnostics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Piramal"},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013995","name":"Sanofi Genzyme","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100013995","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100011725","name":"Servier","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100011725","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100007723","name":"Takeda","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007723","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006259","name":"Teva","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006259","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011944","name":"UCB","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011944","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","prd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Parkinsonism & Related Disorders"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.parkreldis.2018.05.003","type":"journal-article","created":{"date-parts":[[2018,5,9]],"date-time":"2018-05-09T02:45:44Z","timestamp":1525833944000},"page":"70-75","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Bdnf variant is associated with milder motor symptom severity in early-stage Parkinson's disease"],"prefix":"10.1016","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5245-3832","authenticated-orcid":false,"given":"D. Luke","family":"Fischer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peggy","family":"Auinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John L.","family":"Goudreau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katrina L.","family":"Paumier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allyson","family":"Cole-Strauss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher J.","family":"Kemp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jack W.","family":"Lipton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2571-6753","authenticated-orcid":false,"given":"Caryl E.","family":"Sortwell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"16","key":"10.1016\/j.parkreldis.2018.05.003_bib1","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1002\/mds.22759","article-title":"Levodopa response in early Parkinson's disease","volume":"24","author":"Hauser","year":"2009","journal-title":"Mov. Disord. : Official J. Mov. Disord. Soc."},{"issue":"3","key":"10.1016\/j.parkreldis.2018.05.003_bib2","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/mds.26913","article-title":"Biomarker-driven phenotyping in Parkinson's disease: a translational missing link in disease-modifying clinical trials","volume":"32","author":"Espay","year":"2017","journal-title":"Mov. Disord. : Official J. Mov. Disord. Soc."},{"issue":"1","key":"10.1016\/j.parkreldis.2018.05.003_bib3","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2217\/nmt.14.38","article-title":"Pharmacogenetic considerations in the treatment of Parkinson's disease","volume":"5","author":"Kurzawski","year":"2015","journal-title":"Neurodegener. Dis. Manag."},{"issue":"5","key":"10.1016\/j.parkreldis.2018.05.003_bib4","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0036199","article-title":"alpha-Synuclein genetic variants predict faster motor symptom progression in idiopathic Parkinson disease","volume":"7","author":"Ritz","year":"2012","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.parkreldis.2018.05.003_bib5","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1212\/WNL.0000000000001953","article-title":"Greater motor progression in patients with Parkinson disease who carry LRRK2 risk variants","volume":"85","author":"Oosterveld","year":"2015","journal-title":"Neurology"},{"issue":"18","key":"10.1016\/j.parkreldis.2018.05.003_bib6","doi-asserted-by":"crossref","first-page":"4401","DOI":"10.1523\/JNEUROSCI.0348-04.2004","article-title":"Variant brain-derived neurotrophic factor (BDNF) (Met66) alters the intracellular trafficking and activity-dependent secretion of wild-type BDNF in neurosecretory cells and cortical neurons","volume":"24","author":"Chen","year":"2004","journal-title":"J. Neurosci. : Official J. Soc. Neurosci."},{"key":"10.1016\/j.parkreldis.2018.05.003_bib7","unstructured":"D.o.S.N.P. dbSNP, dbSNP Build ID: rs6265. http:\/\/www.ncbi.nlm.nih.gov\/SNP\/snp_ref.cgi?searchType=adhoc_search&type=rs&rs=rs6265)."},{"issue":"11","key":"10.1016\/j.parkreldis.2018.05.003_bib8","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1007\/s10038-005-0295-z","article-title":"The role of G196A polymorphism in the brain-derived neurotrophic factor gene in the cause of Parkinson's disease: a meta-analysis","volume":"50","author":"Zintzaras","year":"2005","journal-title":"J. Hum. Genet."},{"issue":"11","key":"10.1016\/j.parkreldis.2018.05.003_bib9","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1212\/01.wnl.0000187075.81589.fd","article-title":"BDNF genetic variants are associated with onset age of familial Parkinson disease: GenePD Study","volume":"65","author":"Karamohamed","year":"2005","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.parkreldis.2018.05.003_bib10","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1136\/jnnp.2008.154294","article-title":"BDNF val66met influences time to onset of levodopa induced dyskinesia in Parkinson's disease","volume":"80","author":"Foltynie","year":"2009","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.parkreldis.2018.05.003_bib11","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.parkreldis.2017.11.339","article-title":"Dopamine receptors and BDNF-haplotypes predict dyskinesia in Parkinson's disease","volume":"47","author":"Kusters","year":"2018","journal-title":"Park. Relat. Disord."},{"issue":"2","key":"10.1016\/j.parkreldis.2018.05.003_bib12","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s12031-014-0276-9","article-title":"Sequence variants in SLC6A3, DRD2, and BDNF genes and time to levodopa-induced dyskinesias in Parkinson's disease","volume":"53","author":"Kaplan","year":"2014","journal-title":"J. Mol. Neurosci."},{"issue":"7","key":"10.1016\/j.parkreldis.2018.05.003_bib13","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/0166-2236(90)90110-V","article-title":"Primate models of movement disorders of basal ganglia origin","volume":"13","author":"DeLong","year":"1990","journal-title":"Trends Neurosci."},{"issue":"19","key":"10.1016\/j.parkreldis.2018.05.003_bib14","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1212\/WNL.0b013e3182919029","article-title":"Increased motor cortical facilitation and decreased inhibition in Parkinson disease","volume":"80","author":"Ni","year":"2013","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.parkreldis.2018.05.003_bib15","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/nn1699","article-title":"BDNF val66met polymorphism is associated with modified experience-dependent plasticity in human motor cortex","volume":"9","author":"Kleim","year":"2006","journal-title":"Nat. Neurosci."},{"issue":"5","key":"10.1016\/j.parkreldis.2018.05.003_bib16","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1093\/cercor\/bhp189","article-title":"BDNF val66met polymorphism influences motor system function in the human brain","volume":"20","author":"McHughen","year":"2010","journal-title":"Cerebr. Cortex"},{"issue":"45","key":"10.1016\/j.parkreldis.2018.05.003_bib17","doi-asserted-by":"crossref","first-page":"10099","DOI":"10.1523\/JNEUROSCI.2680-04.2004","article-title":"The brain-derived neurotrophic factor val66met polymorphism and variation in human cortical morphology","volume":"24","author":"Pezawas","year":"2004","journal-title":"J. Neurosci. : Official J. Soc. Neurosci."},{"key":"10.1016\/j.parkreldis.2018.05.003_bib18","article-title":"Outcomes in early stage Parkinson's disease patients may Be influenced by the BDNF Val66Met polymorphism","volume":"76","author":"Hacker","year":"2014","journal-title":"Ann. Neurol."},{"issue":"3","key":"10.1016\/j.parkreldis.2018.05.003_bib19","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1056\/NEJM199301213280305","article-title":"Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease","volume":"328","author":"Parkinson Study Group","year":"1993","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.parkreldis.2018.05.003_bib20","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1002\/mds.26271","article-title":"Movement disorder society tremor rating scale task, proposing a Parkinson's disease-specific tremor scale from the MDS-UPDRS","volume":"30","author":"Forjaz","year":"2015","journal-title":"Mov. Disord. Official J. Mov. Disord. Soc."},{"issue":"4","key":"10.1016\/j.parkreldis.2018.05.003_bib21","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1001\/jamaneurol.2013.6233","article-title":"Parkinson disease subtypes","volume":"71","author":"Thenganatt","year":"2014","journal-title":"JAMA Neurol."},{"issue":"6","key":"10.1016\/j.parkreldis.2018.05.003_bib22","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1001\/jamaneurol.2014.391","article-title":"Measuring disease progression in early Parkinson disease: the national Institutes of Health exploratory trials in Parkinson disease (NET-PD) experience","volume":"71","author":"Parashos","year":"2014","journal-title":"JAMA Neurol."},{"issue":"12","key":"10.1016\/j.parkreldis.2018.05.003_bib23","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1016\/j.parkreldis.2015.10.006","article-title":"Minimal clinically important difference on the Motor Examination part of MDS-UPDRS","volume":"21","author":"Horvath","year":"2015","journal-title":"Park. Relat. Disord."},{"issue":"10","key":"10.1016\/j.parkreldis.2018.05.003_bib24","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/S1474-4422(15)00178-7","article-title":"Diagnosis of Parkinson's disease on the basis of clinical and genetic classification: a population-based modelling study","volume":"14","author":"Nalls","year":"2015","journal-title":"Lancet Neurol."},{"issue":"10","key":"10.1016\/j.parkreldis.2018.05.003_bib25","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1002\/mds.25122","article-title":"Calibration of unified Parkinson's disease rating scale scores to Movement Disorder Society-unified Parkinson's disease rating scale scores","volume":"27","author":"Goetz","year":"2012","journal-title":"Mov. Disord. : Official J. Mov. Disord. Soc."},{"issue":"1","key":"10.1016\/j.parkreldis.2018.05.003_bib26","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/acn3.371","article-title":"Common variant rs356182 near SNCA defines a Parkinson's disease endophenotype","volume":"4","author":"Cooper","year":"2017","journal-title":"Ann. Clin. Translat. Neurol."}],"container-title":["Parkinsonism & Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802018302323?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802018302323?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:15:37Z","timestamp":1761178537000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1353802018302323"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":26,"alternative-id":["S1353802018302323"],"URL":"https:\/\/doi.org\/10.1016\/j.parkreldis.2018.05.003","relation":{},"ISSN":["1353-8020"],"issn-type":[{"value":"1353-8020","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bdnf variant is associated with milder motor symptom severity in early-stage Parkinson's disease","name":"articletitle","label":"Article Title"},{"value":"Parkinsonism & Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.parkreldis.2018.05.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}